AstraZeneca gets new Tagrisso OK as drug succeeds in ...
AstraZeneca's Tagrisso, approved by the FDA for use with chemotherapy, shows improved outcomes for EGFR-mutated non-small cell lung cancer, extending progression-free survival by nine months over monotherapy. New trial data supports its early use and effectiveness in unresectable cases, reinforcing its status as a key treatment.
Reference News
AstraZeneca gets new Tagrisso OK as drug succeeds in ...
AstraZeneca's Tagrisso, approved by the FDA for use with chemotherapy, shows improved outcomes for EGFR-mutated non-small cell lung cancer, extending progression-free survival by nine months over monotherapy. New trial data supports its early use and effectiveness in unresectable cases, reinforcing its status as a key treatment.